Table 1.
Clinical characteristics of one-year liver transplantation surviving and non-surviving patients.
| 1 Year Non-Surviving Patients (n = 16) | 1 Year Surviving Patients (n = 129) | p | |
|---|---|---|---|
| Serum TAC (nmol/mL)—median (p 25–75) | 2.88 (2.29–4.00) | 4.20 (3.40–5.02) | 0.001 |
| Serum melatonin (pg/mL)—median (p 25–75) | 2.51 (2.13–3.34) | 4.59 (2.73–6.89) | 0.001 |
| Serum malondialheyde (nmol/mL)—median (p 25–75) | 3.71 (3.40–5.66) | 2.96 (2.29–4.18) | 0.01 |
| Serum alpha-fetoprotein (ng/dL)—median (p 25–75) | 11.0 (4.0–194.0) | 7.0 (3.7–25.2) | 0.44 |
| Protein (g/dL)—median (p 25–75) | 7.10 (5.80–7.65) | 6.70 (6.10–7.10) | 0.64 |
| Nodules size (cm)—median (p 25–75) | 3.5 (1.7–5.0) | 3.0 (2.0–3.5) | 0.41 |
| MELD score—median (p 25–75) | 15 (12–18) | 15 (12–18) | 0.95 |
| Leukocytes count—median × 103/mm3 (p 25–75) | 4.89 (3.68–7.76) | 4.75 (3.51–6.36) | 0.68 |
| Creatinine (mg/dL)—median (p 25–75) | 1.01 (0.79–1.10) | 0.90 (0.79–1.06) | 0.37 |
| BMI (kg/m2)—median (p 25–75) | 28.53 (24.07–31.39) | 27.66 (24.55–30.48) | 0.53 |
| Albumin (g/dL)—median (p 25–75) | 3.47 (3.00–3.94) | 3.32 (2.90–4.06) | 0.83 |
| Age of liver recipient (years)—median (p 25–75) | 57 (53–63) | 58 (52–62) | 0.76 |
| Age of liver donor (years)—median (p 25–75) | 62 (50–72) | 52 (36–63) | 0.03 |
| Female—n (%) | 0 | 19 (14.7) | 0.13 |
| Ascites—n (%) | 3 (18.8) | 55 (42.6) | 0.10 |
| Infiltration—n (%) | 5 (31.3) | 39 (30.2) | 0.99 |
| Inside Milan criteria prior to LT—n (%) | 15 (93.8) | 124 (96.1) | 0.51 |
| Inside Milan criteria after LT—n (%) | 11 (68.8) | 107 (82.9) | 0.19 |
| Macrovascular invasion—n (%) | 0 | 7 (5.4) | 0.99 |
| Microvascular invasion—n (%) | 4 (25.0) | 27 (20.9) | 0.75 |
| Multinodular tumor—n (%) | 5 (31.3) | 38 (29.5) | 0.99 |
| Portal hypertension—n (%) | 12 (75.0) | 89 (69.0) | 0.78 |
| Degree of tumor differentiation—n (%) | 0.55 | ||
| Well | 12 (80.0) | 95 (73.7) | |
| Moderate | 3 (13.7) | 31 (24.0) | |
| Poor | 1 (6.3) | 3 (2.3) | |
| Child-Pugh score—n (%) | 0.27 | ||
| A | 11 (68.8) | 61 (47.3) | |
| B | 3 (18.8) | 38 (29.5) | |
| C | 2 (12.5) | 30 (23.3) | |
| ABO blood type—n (%) | 0.89 | ||
| A | 6 (37.5) | 59 (45.7) | |
| B | 2 (12.5) | 10 (7.8) | |
| O | 7 (43.8) | 53 (41.1) | |
| AB | 1 (6.3) | 7 (5.4) | |
| Transplantation technique—n (%) | 0.78 | ||
| By-pass | 6 (37.5) | 42 (32.6) | |
| Piggy back | 10 (62.5) | 87 (67.4) | |
| Treatment prior to LT—n (%) | 11 (68.8) | 72 (55.8) | 0.78 |
| Percutaneous ethanol injection (PEI)—n (%) | 7 (43.8) | 28 (21.7) | 0.07 |
| Radiofrequency ablation (RFA)—n (%) | 0 | 8 (6.2) | 0.60 |
| Transarterial chemoembolization (TACE)—n (%) | 4 (25.0) | 29 (22.5) | 0.76 |
| Liver resection—n (%) | 0 | 3 (2.3) | 0.99 |
| Mixed treatment—n (%) | 0 | 4 (3.1) | 0.99 |
TAC: total antioxidant capacity; MELD: model for end-stage liver disease; BMI: body mass index.